Sorafenib Market Research Report 2026-2030 - Increasing Cancer Incidence Spurs Sorafenib Market Expansion

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Sorafenib Market Report 2026" has been added to ResearchAndMarkets.com's offering.

This report delves into vital market aspects, offering detailed insights into industry size, trends, and competitive dynamics. It provides an all-encompassing perspective on current and future industry scenarios.

The global sorafenib market has demonstrated a steady growth trajectory, driven by a variety of factors. The market size is projected to expand from $1.29 billion in 2025 to $1.34 billion in 2026, reflecting a compound annual growth rate (CAGR) of 3.8%. This growth is primarily driven by the historical success of targeted kinase inhibitors, increasing cancer prevalence, multipurpose approval of sorafenib, strong R&D pipelines in oncology, and market expansion fueled by patents.

Looking ahead, the sorafenib market is expected to reach $1.56 billion by 2030, with a CAGR of 3.9%. Key drivers include the rising production of generic oncology drugs, heightened cancer diagnosis rates, an increased focus on cost-effective cancer treatments, expanding oncology infrastructure, and ongoing research into combination therapies. Emerging trends indicate a growing reliance on targeted cancer therapies, a rise in generic sorafenib product availability, and greater adoption in treating liver and kidney cancers.

The soaring incidence of cancer continues to propel the market forward. Cancer's prevalence is heightened by factors such as aging populations, lifestyle risks, and advanced diagnostic techniques. Sorafenib plays a crucial role in cancer treatment by inhibiting pathways that promote tumor growth, offering therapeutic benefits for advanced renal cell and hepatocellular carcinomas. According to the National Center for Biotechnology Information, nearly 1,958,310 new cancer cases and 609,820 cancer-related deaths were reported in the U.S. in 2023, underscoring the growing demand for effective treatments.

Increased healthcare spending is another pivotal factor influencing market growth. With a notable rise in chronic diseases, the need for long-term therapies is more pronounced, thereby driving healthcare expenditure. This spending surge enhances sorafenib adoption by broadening access to advanced treatments, supporting early diagnosis, and facilitating affordability. For instance, UK healthcare expenditure saw a nominal increase of 5.6% from 2022 to 2023, highlighting the sector's expansion.

In a significant industry move, Lotus Pharmaceuticals Co. Ltd., a Taiwan-based company, acquired Teva Pharmaceutical Industries Ltd. in June 2024. This acquisition bolsters Lotus's position in the generics market, enhancing its product portfolio and operational expertise, particularly in oncology where Teva has strong capabilities.

The market's competitive landscape features prominent players such as Bayer AG, Mylan N.V., Cipla Limited, Dr. Reddy's Laboratories Ltd ., Natco Pharma, and more. Notably, North America emerged as the leading region in the sorafenib market in 2025. The comprehensive regional analysis encompasses Asia-Pacific, Southeast Asia, Europe, North and South America, the Middle East, and Africa.

The Sorafenib Market Global Report 2026 equips strategists, marketers, and senior management with essential insights to evaluate the flourishing market. This comprehensive report delves into the current growth trends and forecasts for the sorafenib market over the next decade and beyond.

Markets Covered:

• By Product: Patented Drugs; Generic Drugs
• By Distribution Channel: Hospital Pharmacies; Drug Store And Retail Pharmacies; Online Pharmacies
• By Application: Kidney Cancer; Liver Cancer; Thyroid Cancer

Subsegments:

• By Patented Drugs: Nexavar
• By Generic Drugs: Generic Sorafenib Tosylate; Other Generic Variants

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Regions: Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Time Series: Five years historic and ten years forecast.

Data: Market size and growth ratios, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional data with historic and forecast analysis, competitor market share, market segments.

Delivery Format: Available in Word, PDF, or Interactive Report + Excel Dashboard.

Key Attributes

The companies featured in this Sorafenib market report include:

• Bayer AG
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Cipla Limited
• Dr. Reddy's Laboratories Ltd .
• Natco Pharma
• Hikma Pharmaceuticals PLC
• Beacon Pharmaceuticals Ltd.
• Hetero Healthcare Ltd.
• Aprazer Healthcare Private Limited
• Wellona Pharma
• Anant Pharmaceuticals Pvt. Ltd.
• Intelicure Lifescience
• Zydus Lifesciences
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Accord Healthcare
• Sandoz
• MSN Laboratories
• Alvogen

For more information about this report visit https://www.researchandmarkets.com/r/xsn6fg

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Sorafenib Market

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900